Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corp (DXR) delivers critical advancements in blood volume measurement through its FDA-cleared BVA-100 technology. This page provides investors and healthcare professionals with centralized access to official news, financial updates, and clinical developments related to DXR’s diagnostic innovations.
Track press releases covering product milestones, peer-reviewed research validations, and strategic partnerships. Stay informed about quarterly earnings, regulatory filings, and advancements in fluid management diagnostics. All content is sourced directly from verified company communications to ensure accuracy.
Key updates include BVA-100 adoption metrics, clinical trial outcomes, and operational expansions. Bookmark this page for real-time insights into DXR’s role in transforming patient diagnostics through precise blood volume analysis. Regularly updated to serve as your primary resource for unbiased, factual Daxor Corp developments.
Daxor Corporation (NYSE: DXR) announced the completion of patient enrollment and commencement of data analysis for a multi-center observational study utilizing the BVA-100 blood volume measurement technology in hospitalized COVID-19 patients. Conducted by NYU Langone Health and others, the study aims to investigate fluid imbalances in COVID-19 patients, revealing significant capillary damage and blood volume deficits. The results are expected to enhance treatment strategies and outcomes for critically ill patients.
Daxor Corporation (NYSE: DXR) has received a new patent (U.S. Patent No. 11,204,356 B2) for its innovative blood volume analysis technology, aimed at enhancing treatment decisions across various medical conditions. This patent protects a clinical guidance system designed for optimal fluid management, combining unique volume metrics with treatment pathways. CEO Michael Feldschuh emphasized that this marks a significant milestone in advancing healthcare. Daxor is actively developing solutions supported by the National Institutes of Health, aiming to improve outcomes for conditions like heart failure.
Daxor Corporation (NYSE: DXR) presented new studies validating its BVA-100 blood test at the American Heart Association Scientific Sessions. The test helps identify heart failure patient-specific phenotypes and detect true anemia. The first study on patients with left ventricular assist devices revealed blood volume variations, while the second study found traditional hematocrit measures lack sensitivity for true anemia. The findings support the increasing adoption of BVA technology in optimizing heart failure management.
Daxor Corporation (NYSE: DXR) announced significant findings at the NeuroCritical Care Society's 19th Annual Meeting, showcasing the effectiveness of their BVA-100 blood test in managing non-traumatic subarachnoid hemorrhage (nSAH). The study revealed that 69% of physicians altered their treatment strategies based on BVA results, preferring it over invasive methods. Previous studies indicated a 54% change in management and a 66% reduction in ICU mortality linked to BVA tests. These results underscore Daxor's role in improving patient outcomes through enhanced blood volume management.
Daxor Corporation (NYSE: DXR) has been awarded a SBIR/STTR matching fund grant of $200K from Launch Tennessee, linked to a Phase II award from the Department of Defense. This funding will support the development of their next-generation point-of-care blood volume analyzer. The grant is part of a competitive selection aimed at encouraging innovation and job creation in Tennessee, where over 80 applications were received. Daxor's CEO highlighted the importance of this grant for advancing their technology and enhancing patient outcomes.
Daxor Corporation (NYSE: DXR) presented new findings at the Heart Failure Society of America Annual Scientific Meeting 2021, emphasizing the significance of the BVA-100 blood test in managing heart failure. The data illustrated the test's effectiveness in tailoring treatment for patients, especially those with left ventricular assist devices. Notably, studies highlighted improved outcomes for hospitalized patients through blood volume analysis and ultrafiltration techniques. Ongoing clinical trials aim to apply BVA-100 in various settings, enhancing care for over one million heart failure patients in the U.S.
Daxor (NYSE: DXR) will showcase its blood volume measurement technology at the Heart Failure Society of America Annual Scientific Meeting from September 10-13, 2021. The event will feature new clinical trials demonstrating the effectiveness of the BVA-100 test. Daxor's Chief Scientific Officer stated this year’s program is the most comprehensive in the company’s history, highlighting outcomes in patients with left ventricular assist devices and heart failure. The company aims to improve patient outcomes through important clinical studies funded by NIH and the Department of Defense, impacting over 7 million patients in the U.S.
Daxor, a leader in blood volume measurement technology, announced that CEO Michael Feldschuh will present at the 23rd Annual H.C. Wainwright Global Investment Conference held virtually from September 13-15, 2021. His presentation will cover the company's latest updates, business model, and growth strategy, available from September 13th at 7:00 AM ET. Investors can register for the conference and schedule one-on-one meetings with Feldschuh. Daxor is known for the BVA-100, the first FDA-cleared diagnostic blood test for precise blood volume quantification.
Daxor Corporation (NYSE: DXR) announced significant growth in its blood volume diagnostic division, reporting a 26.5% increase in revenue for H1 2021 versus the prior year. CEO Michael Feldschuh highlighted plans for a new point-of-care blood volume analyzer launching in 2022, developed alongside the US DOD. Daxor’s strategy includes strong commercialization, next-gen product development, and improved clinical outcomes, supported by NIH funding for heart failure research. The company aims to expand its market reach significantly, leveraging both internal and external sales forces to enhance performance.
Daxor Corporation (NYSE: DXR) reports a 26.5% revenue increase in its diagnostic division, driven by the commercialization of the BVA-100® Blood Volume Analyzer and new distributor agreements. The company anticipates further growth through a multi-channel distribution model and has opened eight new accounts in 2021. Daxor's next-gen analyzers are set for production in 2022, supported by funding from the U.S. Department of Defense. Despite a 7% decrease in net assets to $14.5 million, the company remains optimistic about its commercialization strategy amidst ongoing COVID-19 challenges.
